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Summary statement 
 
Basal lipolysis and adipokine secretion are controlled by autocrine purinergic signaling via 
P2Y2 receptors in human adipocytes. 
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ABSTRACT 
 
White adipocytes are key regulators of metabolic homeostasis, which release stored energy as 
free fatty acids via lipolysis. Adipocytes possess both basal and stimulated lipolytic capacity, 
but limited information exists regarding the molecular mechanisms that regulate basal lipolysis. 
Here, we describe a mechanism whereby autocrine purinergic signaling and constitutive P2Y2 
receptor activation suppresses basal lipolysis in primary human in vitro differentiated 
adipocytes. We found that human adipocytes possess cytoplasmic calcium tone due to ATP 
secretion and constitutive P2Y2 receptor activation. Pharmacological antagonism or 
knockdown of P2Y2 receptors increases intracellular cAMP levels and enhances basal lipolysis. 
P2Y2 receptor antagonism works synergistically with phosphodiesterase inhibitors in elevating 
basal lipolysis, but is dependent upon adenylate cyclase activity. Mechanistically, we suggest 
that the increased calcium tone exerts an anti-lipolytic effect by suppression of calcium-
sensitive adenylate cyclase isoforms. We also observed that acute enhancement of basal 
lipolysis following P2Y2 receptor antagonism alters the profile of secreted adipokines leading 
to longer term adaptive decreases in basal lipolysis. Our findings reveal that basal lipolysis and 
adipokine secretion are controlled by autocrine purinergic signaling in human adipocytes. 
 
 
INTRODUCTION 
 
White adipose tissue (WAT) is the primary site of long-term energy storage within mammals. 
WAT comprises of a diverse range of cells, of which the predominant cell type is white 
adipocytes. White adipocytes play a pivotal role in the endocrine function of WAT via the 
production and release of adipokines to regulate systemic metabolism (Halberg et al. 2008). 
However, their primary function is to facilitate long-term storage of excess nutrients within 
large lipid droplets. These lipid droplets give white adipocytes their distinctive unilocular 
morphology. Adipocytes are highly dynamic cells, which store excess energy in the form of 
triglycerides in the fed state via lipogenesis and release energy in the form of free fatty acids 
during fasting via lipolysis (Rutkowski et al. 2015). The metabolic activity of white adipocytes 
is regulated tightly by hormones and the autonomic nervous system to achieve whole body 
metabolic homeostasis. As such, loss of adipocyte control is associated with cardiovascular 
risk and obesity (Nielsen et al. 2014; Rosen & Spiegelman 2006). Adipocytes possess both a 
basal and stimulated lipolytic capacity. The most well characterised stimulated lipolytic 
pathway is mediated by sympathetic nerve stimulation of WAT via β-adrenoreceptors. Upon 
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activation of β-adrenoreceptors, Gs-mediated stimulation of adenylate cyclase is initiated, 
which causes an elevation in cytoplasmic cyclic AMP. Subsequently, this activates protein 
kinase A, which in turn phosphorylates hormone sensitive lipase (HSL) and perilipins on the 
surface of the lipid droplet to allow translocation of HSL to the lipid droplet (Miyoshi et al. 
2006), where HSL, in combination with adipose triglyceride lipase (ATGL) and monoglyceride 
lipase (MGL), catalyses the hydrolysis of triglycerides to free fatty acids and glycerol 
molecules. The free fatty acids can then be released into the bloodstream where they are able 
to travel to distant organs and be utilised as a cellular energy source (Ahmadian et al. 2010). 
Despite the  importance of basal lipolysis in regulating adipose tissue volume and the level of 
circulating free fatty acids (Heckmann et al. 2014; Miyoshi et al. 2008; Rydén & Arner 2017), 
the molecular mechanisms regulating basal lipolysis are less well defined than the stimulated 
lipolytic pathways.  
 
The concentration of free cytoplasmic Ca2+ and the rhythmicity of Ca2+ oscillations within the 
cytoplasm, are critical regulators of many important processes within mammalian cells, 
including gene expression, cytoskeletal rearrangement, secretion and metabolism (Clapham 
2007). In adipocytes, intracellular Ca2+ is known to be a key regulator of adipocyte 
differentiation (Shi et al. 2000) and metabolism (Arruda & Hotamisligil 2015), but cell surface 
receptors that evoke intracellular Ca2+ responses and how they are linked to metabolic control 
of human adipocytes are poorly defined. 
 
Adipocytes in white adipose tissue are innervated by the sympathetic branch of the autonomic 
nervous system (Bartness et al. 2014). Increased sympathetic tone drives lipolysis through the 
action of noradrenaline on -adrenergic receptors expressed at the adipocyte cell surface 
(Ahmadian et al. 2010). Consequently, local denervation of white adipose depots in pre-clinical 
models leads to fat pad expansion (Bowers et al. 2004). Sympathetic neurons release ATP as a 
co-transmitter with noradrenaline during innervation of a range of tissues (Kennedy 2015). In 
addition, ATP is also released physiologically by cells during inflammation and injury where 
it acts as a danger-associated molecular pattern (Gorini et al. 2013). We and others have also 
documented constitutive release of ATP by differing mammalian cell types (Corriden & Insel 
2010; Sivaramakrishnan et al. 2012), which produces a resting steady concentration of ATP 
close to the cell surface and tonic activation of some purinergic receptor subtypes. Extracellular 
ATP can evoke changes in cytoplasmic Ca2+ via activation of P2X and P2Y cell surface 
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purinergic receptors. P2X receptors (P2X1-7) are non-selective ligand-gated ion channels 
activated by extracellular ATP that are directly permeate to Ca2+ (North 2002). P2Y receptors 
(P2Y1,2,4,6,11,12,13 and 14) are G protein-coupled receptors that are activated by ATP, ADP, UTP, 
UDP and UDP-sugars in a subtype-specific fashion (von Kügelgen & Hoffmann 2016). 
P2Y1,2,4,6 and 11 are Gq-coupled receptors, so upon activation they elevate cytoplasmic Ca
2+ 
through IP3-mediated release of Ca
2+ stored in the endoplasmic reticulum. P2Y13 and P2Y14 
receptors are Gi-coupled and evoke pertussis-toxin sensitive intracellular Ca
2+ responses. 
P2Y12 receptors are also Gi-coupled, but do not evoke intracellular Ca
2+ responses, instead they 
positively regulate intracellular Ca2+ responses evoked by other P2Y receptors (Micklewright 
et al. 2018). The repertoire and function of cell surface purinergic receptors expressed by 
human adipocytes is currently unclear. Here we sought to determine what purinergic receptors 
are expressed by primary human in vitro differentiated adipocytes and investigate their 
potential in regulating basal lipolysis. 
 
RESULTS 
ATP, ADP and UTP-evoked intracellular Ca2+ responses in human adipocytes 
 
A representative image of human adipose-derived mesenchymal stromal cells differentiated to 
mature adipocytes following the habituation protocol is shown in Fig 1A. Application of 
exogenous ATP, ADP and UTP evoked intracellular Ca2+ responses in adipocytes (Fig 1B) 
with a rank order of potency of ADP (EC50 239 ± 48.1 nM; N=6) > ATP (EC50 1.84 ± 1.42 μM; 
N=6) > UTP (EC50 13.0 ± 4.6 μM; N=6) (Fig 1C).  The magnitude of the responses at maximal 
agonist concentrations also had the rank order of ADP > ATP > UTP (Fig 1D). In vitro 
differentiated adipocytes were unresponsive to UDP (<30 μM) and UDP-glucose (<100 μM) 
(N=6) (data not shown).  
 
ATP responses were metabotropic in nature as responses persisted in the absence of 
extracellular Ca2+ (Figs 1E,F), but were abolished following phospholipase C inhibition with 
U73122 (Figs 1G,H). However, the responses to ATP decreased in the absence of extracellular 
calcium, which suggests that extracellular calcium is important for the magnitude of the 
response. We next used selective receptor antagonists to probe the molecular basis of 
nucleotide-evoked Ca2+ responses in human adipocytes. ATP-evoked responses were 
attenuated following selective antagonism of P2Y1, P2Y2 and P2Y12 receptors with MRS2500 
(IC50 415 ± 160 nM; N=6), AR-C118925XX (IC50 683 ± 116 nM; N=6) and PSB-0739 (IC50 > 
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10µM; N=6), respectively (Table S1, Figs 2A-D). The responses could be inhibited further by 
combining P2Y1, P2Y2 and P2Y12 selective antagonists (Fig 2E), suggesting that in addition 
to the ATP/UTP-activated P2Y2 receptor, ADP-activated receptors P2Y1 and P2Y12 actively 
contribute to the ATP response. This is likely to be due to ectonucleotidase breakdown of 
extracellular ATP to ADP (Yegutkin 2008). Contribution of P2Y1 receptors to the ATP/ADP 
response is expected due to its Gq coupling, however the contribution of the Gi-coupled P2Y12 
receptor is less expected, though not unprecedented as it has been shown in other cell types 
(Micklewright et al., 2018). In addition, P2Y1 (MRS2500; IC50 77.1 ± 37.5 nM; N=6) or P2Y12 
(PSB-0739; IC50 64.0 ± 56.5 nM; N=6) receptor antagonism attenuated ADP-evoked Ca
2+ 
signalling in adipocytes (Figs 2F,H), with further attenuation observed when the antagonists 
were combined (Fig 2I). A role for P2Y12 and Gi-coupling was further substantiated as 
pertussis toxin, an inhibitor of Gi-signalling (Katada et al. 1983), inhibited both the ATP and 
ADP-evoked intracellular Ca2+ responses in human adipocytes (Figs 2J,K).   
 
P2Y receptor expression in human adipocytes and human adipose tissue 
Analysis by quantitative RT-PCR revealed a diverse expression profile of purinergic receptors 
in human adipocytes, including P2X4-7, P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12 and P2Y13, 
whereas P2X1, P2X2, P2X3 and P2Y14 are not expressed (Fig 3A). The same receptor subtypes 
were detected by immunocytochemistry in adipocytes in vitro (Fig 3B). The expression of 
P2Y1, P2Y2 and P2Y12 is supported by the functional pharmacology presented (Fig 2). 
However, despite detection at the mRNA and protein level, the use of selective antagonists for 
P2X4 (≤ 30 μM PSB12062), P2X7 (≤ 10 μM A438079), P2Y6 (≤ 10 μM MRS2578), P2Y11 (≤ 
10 μM NF340) and P2Y13 (≤ 3 μM MRS2211) had no effect on ATP and/or ADP-evoked 
intracellular Ca2+ responses in adipocytes (Table S1) suggesting these subtypes are not 
involved under the conditions tested. P2Y1, P2Y2 and P2Y12 expression was also confirmed in 
adipocytes in sections of human subcutaneous adipose tissue (Fig 3C).  
 
Constitutive P2Y2 receptor activity produces intracellular Ca2+ tone  
Extracellular ATP is known to act both as a paracrine and autocrine signal, and we and others 
have previously observed some mammalian cells to have a halo of extracellular ATP due to 
constitutive release (Corriden & Insel 2010; Sivaramakrishnan et al. 2012). To this end, we 
sought to investigate the ability of human adipocytes to secrete ATP and the impact this has on 
homeostasis. Bulk phase luminometry measurements of ATP revealed the ability of human 
adipocytes to condition the culture medium with approximately 50nM ATP (Fig 4A), which is 
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likely to be an underestimation of the acutely pericellular ATP concentration. Scavenging 
extracellular ATP with apyrase caused a reduction in the resting level of cytoplasmic Ca2+ in 
human adipocytes (Fig 4B). These data suggest that extracellular ATP generates intracellular 
Ca2+ tone in human adipocytes, so we explored this further by investigating whether 
constitutive activity of P2Y1, P2Y2 and P2Y12 receptors contribute to resting cytoplasmic Ca
2+ 
levels. There was some variability in the resting cytoplasmic Ca2+ concentration between 
donors, as well as in the presence of different vehicle controls (water or 0.1% DMSO), however 
pairwise comparisons of the effect of each antagonist versus their respective vehicle control 
revealed that antagonism of either P2Y1 or P2Y12 had no significant effect of resting 
cytoplasmic Ca2+ (Fig 4C,E). However, a marked significant reduction was observed following 
selective P2Y2 receptor antagonism (Fig 4D). In these experiments, resting cytoplasmic Ca
2+ 
was reduced from approximately 125 nM to 50 nM free Ca2+, suggesting that constitutive P2Y2 
activity, but not P2Y1 or P2Y12, generates intracellular Ca
2+ tone in human adipocytes.  
 
Constitutive P2Y2 receptor activity suppresses lipolysis via an adenylate cyclase-
dependent mechanism 
The lipolytic activity of adipocytes that produces free fatty acids and glycerol is under 
hormonal and nervous control, but also occurs in the absence of lipolytic stimuli (basal 
lipolysis). Basal lipolysis in adipocytes was measured as a time-dependent conditioning of 
culture medium with glycerol in the absence of stimulation.  Under these conditions, adipocytes 
freely released glycerol over a three-hour period (Fig 5). P2Y2 receptor antagonism caused a 
significant increase in the rate of glycerol release, enhancing release by approximately 40% 
after 3 hours (Fig 5A). By comparison, stimulation of adipocytes with EC50 concentrations of 
isoprenaline (75 nM) to mimic nervous stimulation causes a 122 ± 24% (N=3) increase in 
glycerol release versus basal conditions. The P2Y2 receptor antagonist AR-C118925XX 
enhanced basal glycerol release in a concentration-dependent fashion (Fig 5B). To further 
investigate the mechanism by which P2Y2 antagonism increases basal lipolysis we quantified 
cellular cyclic AMP (cAMP), a positive effector of lipolysis in adipocytes, with and without 
AR-C118925XX treatment. AR-C118925XX treatment significantly elevated cellular cAMP 
in adipocytes (Fig 5C). To support these findings, we used lentivirus delivery of shRNA to 
knockdown P2Y2 receptor expression in adipocytes to investigate the impact on lipolysis and 
intracellular cAMP levels. Using this strategy P2Y2 mRNA could be knocked down by 
59.83.7% (N=5; P<0.05) versus scrambled counterparts. The rate of basal lipolysis (Fig 5D) 
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and intracellular cAMP levels (Fig 5E) were both elevated in the P2Y2 knockdown cells versus 
their scrambled counterparts. Interestingly, P2Y2 knockdown adipocytes produced a small lipid 
droplet phenotype compared to their scrambled counterparts (Fig 5F), and the number of 
droplets per cell was significantly increased (Fig 5G). Such phenotypic changes in lipid 
droplets is associated with increased lipid metabolism (Paar et al., 2012). To this end, we 
quantified the amount of neutral lipid stored within scrambled and P2Y2 knockdown adipocytes 
using BODIPY fluorescence, and demonstrated that P2Y2 knockdown cells contained less 
neutral lipid (Fig 5H). Taken together these data suggest that reducing P2Y2 activity by means 
of pharmacological antagonism or gene knockdown increases basal lipolysis in human 
adipocytes. In control experiments, antagonism of either P2Y1 (Fig 5I) or P2Y12 (Fig 5J) did 
not affect the rate of basal lipolysis, which is in line with a lack of effect on resting cytoplasmic 
Ca2+ (Fig 4).  
 
To further understand how inhibition of constitutive P2Y2 receptor activity leads to an increase 
in cAMP and basal lipolysis, we examined the dependency of these effects on the activity of 
phosphodiesterases (PDE) and adenylate cyclase. An elevation in intracellular Ca2+ is known 
to produce an anti-lipolytic effect in adipocytes, which has previously been ascribed to 
activation of Ca2+-sensitive PDE subtypes (Xue et al. 2001). If the underlying mechanism 
through which inhibition of constitutive P2Y2 activity leads to increased intracellular cAMP 
and enhanced lipolysis is via reducing cytoplasmic Ca2+ and PDE activity, it would be expected 
that enhanced lipolysis produced by P2Y2 antagonism would be abolished by PDE inhibition. 
The pan-PDE inhibitor IBMX increased basal lipolysis to a level comparable to that of AR-
C118925XX (Fig 6A). In addition, using subtype-specific antagonists we observed that 
inhibition of PDE3 (cilostamide) and PDE4 (rolipram), but not PDE1 (vinpocetine), PDE2 (PF-
05180999) or PDE7 (BRL50481), increased basal lipolysis (Fig 6A). Cilostamide enhanced 
lipolysis to a level beyond that of rolipram, and is consistent with a dominant role of PDE3 in 
human adipocytes (Snyder et al. 2005). Combining AR-C118925XX with either cilostamide 
or rolipram produced a synergistic enhancement of basal lipolysis (Fig 6A), suggesting the 
effect of P2Y2 antagonism on basal lipolysis is not dependent on the activity of either PDE3 or 
PDE4. Therefore, we looked for an alternative mechanism and explored the dependency of 
adenylate cyclase itself in mediating the effects of P2Y2 antagonism on cAMP and basal 
lipolysis. By RT-PCR analysis, we identified that human adipocytes express adenylate cyclase 
isoforms 1, 2, 3, 4, 5, 6, 7 and 8, but not 9 (Fig 6B). Of these isoforms 5 and 6 are negatively 
regulated by cytoplasmic Ca2+ (Halls & Cooper 2011) and can be selectively inhibited over 
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other isoforms by low concentrations of SQ22,536 (<10 µM) (Brand et al. 2013). Under these 
conditions, 1µM SQ22536 had no significant effect on basal lipolysis (Fig 6C), consistent with 
tonic suppression of adenylate cyclase, but 1µM SQ22536 could inhibit the ability of P2Y2 
antagonism, with AR-C118925XX, to enhance basal lipolysis in adipocytes (Fig 6C). These 
data suggest that the effects of P2Y2 antagonism on basal lipolysis are due to activation of 
Ca2+-sensitive isoforms of adenylate cyclase.  
 
Pharmacological antagonism of P2Y2 leads to acute enhancement of lipolysis. However, we 
observed that the rate of basal lipolysis is diminished after 24 hours following AR-C118925XX 
treatment compared to counterpart cells treated with vehicle control (Fig 7A). We reasoned 
that the increase in basal lipolysis may give rise to initiation of a negative feedback effect due 
to the enhanced secretion of adipokines with anti-lipolytic activity. To this end, we investigated 
the impact of pharmacological manipulation of constitutive P2Y2 activity on the profile of 
secreted adipokines in human adipocytes. Analysis of secreted adipokines by protein array 
revealed changes in the profile of adipokines secreted in response to AR-C118925XX 
treatment (Fig 7B and Table S2). Of particular interest was the dramatically enhanced 
secretion of adipokines with anti-lipolytic activity including adiponectin (Qiao et al. 2011; 
Wedellová et al. 2011) and adipsin (Van Harmelen et al. 1999; Ronti et al. 2006), and  the 
down-regulation of several adipokines that stimulate lipolysis including angiopoietin-like 4 
(ANGPTL4) protein (Gray et al. 2012; La Paglia et al. 2017) and retinol-binding protein 4 (Lee 
et al. 2016) (Fig 7C). 
 
DISCUSSION 
This study has identified a diverse profile of purinergic receptors present in primary human 
adipocytes, however interestingly only P2Y1, P2Y2 and P2Y12 receptors appear to be 
functionally involved in nucleotide-evoked calcium responses. Although P2X4-7 receptors were 
detected at both the mRNA and protein level, the ATP response appears to be mediated by 
metabotropic P2Y receptors, as evidenced by the persistence of response in the absence of 
extracellular calcium, abolishment of the response when PLC was inhibited and no effect of 
selective antagonism of P2X4 and P2X7. P2X4 receptors are known to localise to lysosomes 
and rapidly traffic to and from the plasma membrane in other cell types (Stokes 2013; Ashour 
& Deuchars 2004), which may explain why exogenous application of ATP was unable to 
activate P2X4. A lack of involvement of P2X5 and P2X6 is unsurprising, as these receptors are 
not functional in humans (Torres et al. 1999; Ormond 2006; Kotnis et al. 2010). P2X7 receptors 
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require very high concentrations of ATP to be activated (North 2002), so perhaps in this study, 
the concentration of ATP used was not sufficiently elevated to activate P2X7. In addition, 
several P2Y receptor subtypes (P2Y4, P2Y6, P2Y11 and P2Y13) were also detected in human 
adipocytes, but do not appear to play a functional role in nucleotide-evoked calcium responses 
in these cells. In the case of P2Y4, it is not possible to definitively rule out a role for this 
receptor, due to the absence of a commercially available selective antagonist for P2Y4 
(Jacobson et al. 2009). However, the observation that the response to UTP, the preferred agonist 
for P2Y4, is abolished by selective antagonism of P2Y2 indicates that P2Y4 is unlikely to play 
a role in the UTP-evoked calcium response in human adipocytes. A possible explanation for 
the lack of involvement of P2Y4, P2Y6, P2Y11 and P2Y13 receptors is that P2Y2 receptor 
activation caused heterologous desensitisation of these subtypes (Govindan & Taylor 2012).  
An important caveat to this study is that the Ca2+ responses reported are measurements from 
populations of adipocytes, and therefore variability of responses at the single cell level will be 
lost.  
 
The P2Y2 receptor is capable of sensing extracellular ATP in the nanomolar range (Lazarowski 
et al. 1995), thus the concentration of extracellular ATP released by adipocytes in this study is 
sufficient to activate P2Y2. Here, we report that these properties of the P2Y2 receptor allow it 
to be constitutively active due to the extracellular ATP microenvironment of human 
adipocytes. Furthermore, we provide data to demonstrate the functional importance of this 
constitutive activity in regulation of adipocyte intracellular Ca2+ tone, the rate of basal lipolysis 
and the profile of secreted adipokines. Though this is the first demonstration in human 
adipocytes, we and others have previously demonstrated the role purinergic receptors can play 
in autocrine regulation of mammalian cells due to constitutive or agonist-triggered ATP release 
(Corriden & Insel 2010; Sivaramakrishnan et al. 2012).   
 
In this study, we contribute the acute anti-lipolytic activity of P2Y2 antagonism to a decrease 
in resting cytoplasmic Ca2+. Previous studies have highlighted an importance of free 
cytoplasmic Ca2+ in regulating lipolysis (Xue et al. 2001), though the molecular mechanisms 
underlying this are unclear. Certain PDE isoforms, specifically PDE1 isoforms, are sensitive 
to and activated by Ca2+ (Omori & Kotera 2007) via a Ca2+/calmodulin-dependent mechanism. 
Stimulation of basal lipolysis following P2Y2 antagonism could arise via this mechanism due 
to a decrease in cytoplasmic Ca2+ and the consequent loss of PDE activity, increasing the 
availability of cAMP and promoting lipolysis. However, our findings do not support this 
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mechanism as direct PDE inhibition has a synergistic effect with P2Y2 antagonism on lipolysis. 
Furthermore, use of the vinpocetine, a selective inhibitor of Ca2+/calmodulin-sensitive PDE1 
isoforms, had no effect on basal lipolysis, suggesting PDE1 does not regulate basal lipolysis. 
As the stimulatory action of P2Y2 receptor antagonism on basal lipolysis is completely 
inhibited by the adenylate cyclase inhibitor SQ22,536, we suggest the role of constitutively 
active P2Y2 may be to directly control the activity of adenylate cyclase and acutely regulate 
lipolysis via this route. One interesting observation is that adenylate cyclase inhibition does not 
decrease basal lipolysis, which suggests that adenylate cyclase activity is tonically suppressed. 
This observation is consistent with findings in rodent adipocytes (Juan et al. 2005; Jun et al. 
2006). Our model suggests that adenylate cyclase activity does not contribute to the basal 
lipolytic capacity of adipocytes due to tonic suppression by elevated cytoplasmic Ca2+ (Fig 8). 
However, basal lipolysis occurs even in the absence of adenylate cyclase activity or activation 
of hormone-sensitive lipase (HSL) via the cAMP/PKA signalling axis, which is a known and 
important mediator of hormone and nervous stimulated lipolysis. This may be explained by the 
existence of adipose triglyceride lipase (ATGL), which is a cAMP-independent lipase known 
to regulate basal lipolysis (Miyoshi et al. 2008; Wang et al. 2011).    
 
The correlation between P2Y2 receptor activity, elevated intracellular Ca
2+, cAMP reduction 
and lowered basal lipolysis, has lead us to the hypothesis that constitutive P2Y2 activity 
suppresses adenylate cyclase activity (Fig 8). There is precedence for a role for adipocyte 
cytoplasmic Ca2+ tone in regulating adenylate cyclase activity, as several adenylate cyclase 
isoforms (types 5 and 6) are Ca2+-sensitive (Cioffi et al. 2002). Type 6 in particular has been 
shown to be inhibited by Ca2+-entry through store-operated channels, that are likely to be 
opened following P2Y2 receptor activation. The molecular basis of some of these channels 
have recently been identified in mouse adipocytes, where they control adiponectin secretion 
(Sukumar et al. 2012).    
 
Here we demonstrate that pharmacological inhibition of P2Y2 has a biphasic effect on lipolysis, 
an acute stimulatory effect (within 3 hours) followed by a reduction in lipolysis after 24 hours. 
The consequent reduction may be the result of a change in the profile of secreted adipokines 
following P2Y2 antagonism. Adipocytes can sense and autoregulate their lipolytic capacity 
through autocrine adipokine signalling. There is evidence for a local negative feedback loop 
between increased lipolysis and the release of adiponectin, whereby elevated free fatty acid 
concentrations promote adiponectin secretion (Bernstein et al. 2004; Krzyzanowska et al. 
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2007), which in turn acts on adipocytes to inhibit lipolysis (Qiao et al. 2011).  There is a clear 
link between increased adipocyte metabolism and adipocyte inflammation (Greenberg & Obin 
2006). In obesity the well documented recruitment of macrophages into adipose tissue and 
decreased insulin sensitivity is likely to underlie the enhanced basal lipolysis in inflamed 
adipose tissue (Weisberg et al. 2003), though some inflammatory cytokines also have acute 
actions on adipose function (Zhang et al. 2002). It is interesting therefore that antagonism of 
P2Y2 leads to enhance secretion of several inflammatory cytokines including TGF-and IL-8, 
and markers of acute phase inflammation including serum amyloid A and plasminogen 
activator inhibitor-1. Such factors may be secreted in response to the acute increase in lipolysis 
following AR-C118925XX treatment.    
 
In summary, we provide evidence that constitutive P2Y2 activity is important for the regulation 
of basal lipolysis. We also demonstrate that perturbations in its activity and consequent 
enhanced basal lipolysis alter the profile of secreted adipokines in human in vitro differentiated 
adipocytes. This study highlights the P2Y2 receptor and microenvironmental ATP as novel 
targets for pharmacological manipulation of WAT function. 
 
METHODS 
Chemicals and reagents 
All chemicals were purchased from Sigma-Aldrich (Dorset, UK) unless otherwise stated. 
Selective antagonists were obtained from Tocris Bioscience (Bristol, UK) (P2Y1 MRS2500; 
P2Y2 AR-C118925XX; P2Y6 MRS2578; P2Y11 NF340; P2Y12 PSB-0739; P2Y13 MRS2211; 
P2X4 PSB12062; P2X7 A438079; adenylate cyclase (SQ22,536) and Gi signalling (Pertussis 
toxin). U73122 (phospholipase C) was purchased from Santa Cruz Biotechnology (Texas, DA, 
USA). All isoform selective phosphodiesterase (PDE) inhibitors (PDE1 vinpocetine; PDE2 
PF-05180999; PDE3 cilostamide; PDE4 rolipram; PDE7 BRL50481) were purchased from 
Sigma-Aldrich (Dorset, UK). Nucleotides were purchased from Abcam (Cambridge, UK), 
excluding ADP and UDP (Sigma-Aldrich, Dorset, UK).  
 
Tissue donation 
Subcutaneous abdominal adipose tissue samples were obtained from 48 healthy female 
volunteers, with an average age of 55.5 ± 1.5 (N=45, range 38-75), undergoing elective delayed 
deep inferior epigastric perforator flap operations. All recruited patients were prior breast 
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cancer sufferers who have had mastectomies as part of their cancer treatment and are now in 
remission. Recruited patients had an average body mass index (BMI) value of 27.7 ± 0.5 
(N=34, range 24-35). Patients were normotensive with an average mean arterial pressure of 
98.4 ± 1.6 (N=44). Samples were obtained with the assistance of the plastic surgery team at 
the Norfolk and Norwich University Hospital (NNUH). All volunteers were screened to 
exclude diabetics, patients with infections or cancer and patients on anti-inflammatory 
medication. Informed written consent was obtained from all volunteers prior to participation 
in the study. This study was ethically approved by the London-Stanmore Research Ethics 
Committee (152093) and the Research and Development department at the NNUH 
(2014EC03L).   
 
Primary cell isolation from adipose tissue and in vitro differentiation 
Primary cells were isolated from human subcutaneous adipose tissue using a slightly adapted 
form of standard isolation procedures (Turner et al. 2010). In brief, fresh adipose tissue samples 
were dissected to remove blood vessels, fibrous tissue and skin. The samples were then further 
minced and enzymatically digested with collagenase (type 1A) from Clostridium histolyticum 
(Sigma-Aldrich, Dorset, UK) and bovine pancreatic DNase I (Biomatik, Cambridge, Canada) 
for 30 minutes at 37oC with regular mixing by inversion. The digested tissue samples were then 
passed through a 70 μm cell strainer and centrifuged for 5 minutes at 450 x g, which separated 
the sample into a floating fraction containing mature adipocytes and a pellet containing 
multipotent mesenchymal stromal cells (MSCs). The adipocytes were discarded and the MSCs 
were treated with a red cell lysis buffer, washed and then resuspended in culture media (DMEM 
supplemented with 4.5 g/L glucose, sodium pyruvate, L-glutamine, 10% FBS (v/v), 50 IU/ml 
penicillin and 50 µg/ml streptomycin) and left in a T175 flask overnight in a humidified 
incubator at 37oC with 5% CO2. The following day, the cells were washed twice with PBS to 
remove any non-adherent cells or debris and left in fresh serum-containing media until the cells 
were confluent, at which point they were trypsinised and seeded for experimental use. In this 
study, MSCs were plated at an initial seeding density of 2x104 cells/well in 96 well plates, 
unless otherwise indicated. The cells were then allowed to grow to hyper-confluence over the 
next four days and then the differentiation protocol was initiated by removing the culture media 
and replacing it with differentiation media, which consisted of DMEM supplemented with 10% 
FBS, 50 IU/ml penicillin, 50 µg/ml streptomycin, 0.2 mM indomethacin, 1 μM dexamethasone, 
0.5 mM 3-isobutyl-1-methylxanthine (IBMX) and 100 nM insulin, for 14 days. The 
differentiation media was replaced every four days. After two weeks, the differentiation media 
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was removed and exchanged back to culture media for a further three days before experimental 
use to allow the cells to habituate. In all instances where adipocytes are mentioned in this study, 
they are cells that have undergone the full in vitro differentiation and habituation protocol 
described. MSCs were passaged a maximum of four times for differentiation, although the 
majority of experiments were performed using cells from passage 1 and 2. Only cells that 
displayed >90% differentiated cells (as judged by eye) were deemed adequate for experimental 
use. All experiments were performed using cells from at least three independent donors.   
 
Calcium mobilisation experiments 
Culture media was aspirated off in vitro differentiated adipocytes and the cells were gently 
washed with salt buffered solution (SBS) (pH 7.4), containing 130 mM sodium chloride, 5 mM 
potassium chloride, 1.2 mM magnesium chloride, 1.5 mM calcium chloride, 8 mM D-(+)-
glucose and 10 mM HEPES. The cells were then loaded with 2 μM Fura-2AM (Abcam, 
Cambridge, UK) in SBS supplemented with 0.01% (w/v) pluronic for 1 hour at 37oC while 
being protected from light. The loading buffer was then removed and the cells were washed 
twice with SBS. Where applicable, the cells were incubated for a further 30 minutes with 
vehicle/ antagonists or calcium-free SBS (SBS lacking 1.5 mM calcium chloride, but 
containing 2 mM EGTA, pH 7.4). For pertussis toxin experiments, the pertussis toxin was 
added to the culture media 4 hours prior to commencing the calcium mobilisation experiments. 
All antagonists were dissolved in water or DMSO and were then further diluted in SBS, so that 
a final concentration of 0.1% DMSO was not exceeded, excluding U73122 and MRS2578 
which required a final concentration of 1% DMSO.  Finally, the cells were maintained at 37oC 
and challenged with nucleotides administered by a FlexStation III microplate reader 
(Molecular Devices, San Jose, CA, USA), which also recorded the fluorescence (excitation 
340 nm and 380 nm, emission 510 nm) every three seconds to provide fluorescence ratio (Fratio) 
values. Fratio values at every time point, peak F ratios and area under the curve data were 
extracted using SoftMax Pro 5.4.5 (Molecular Devices, San Jose, CA, USA) software.  
 
Calcium calibration 
In vitro differentiated adipocytes were loaded with Fura-2AM as per the calcium mobilisation 
experiment protocol and then incubated with SBS or Ca2+ free SBS for 30 minutes at 37oC 
prior to challenging the cells with 2 μM ionomycin and recording the changes in intracellular 
calcium levels using a Flexstation III microplate reader. The Grynkiewicz formula 
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(Grynkiewicz et al. 1985) was then utilised to convert Fratio values from calcium mobilisation 
assays to intracellular calcium concentrations. The Grynkiewicz formula is as follows: 
[Ca2+]i = KD x β x (R-Rmin)/(Rmax-R) 
 
Where KD is the KD for Fura2-AM at 37
oC which is 224 nM, β is the maximum fluorescence 
intensity at 380 nm for ionomycin in the absence of calcium divided by the minimum 
fluorescence at 380 nm for ionomycin in the presence of calcium, Rmin is the minimum Fratio 
value for ionomycin in absence of calcium and Rmax is the maximum Fratio value for ionomycin 
in the presence of calcium and R is the Fratio value that needs to be converted. β, Rmax and Rmin 
were calculated by averaging the data from three independent donors.  
 
Immunocytochemistry  
MSCs were seeded onto glass coverslips and differentiated in vitro. All subsequent steps were 
conducted at room temperature unless otherwise stated. Culture media was gently aspirated off 
the cells and the cells were washed with PBS, fixed with 4% paraformaldehyde for 15 minutes 
and then permeabilised with 0.25% Triton X-100 for 10 minutes. Non-specific binding was 
blocked with 1% bovine serum albumin (BSA) and then the cells were incubated with the 
appropriate primary antibody (1:200) overnight at 4oC. Primary antibodies were purchased 
from Santa Cruz Biotechnology (Dallas, TX, USA) (P2X5 Santa Cruz Biotechnology Cat# sc-
15192, RRID:AB_2158092), P2Y12 (Santa Cruz Biotechnology Cat# sc-27152, 
RRID:AB_2155964)), Alomone Labs (Jerusalem, Israel) (P2X4, Alomone Labs Cat# APR-
002, RRID:AB_2040058; P2X7, Alomone Labs Cat# APR-004, RRID:AB_2040068; P2Y1, 
Alomone Labs Cat# APR-009, RRID:AB_2040070; P2Y4, Alomone Labs Cat# APR-006, 
RRID:AB_2040080; P2Y6, Alomone Labs Cat# APR-011, RRID:AB_2040082; P2Y11, APR-
015; P2Y13 Alomone Labs Cat# APR-015, RRID:AB_2040072) and abcam (Cambridge, UK) 
(P2Y2, Abcam Cat# ab10270, RRID:AB_297008). All antibodies used were polyclonal and 
raised in rabbits, excluding those purchased from Santa Crux Biotechnology, which were raised 
in goats. Excess primary antibody was removed and successful binding was detected using 
rabbit anti-goat (Abcam, Cambridge, UK) or goat anti-rabbit (Thermo Fisher 
Scientific, Waltham, MA, USA) Alexa Fluor 488-conjugated secondary antibodies (1:1000 
dilution). Finally, cells were mounted using VectaShield containing 1.5 µg/ml DAPI (Vector 
Laboratories, Peterborough, UK) and imaged using a Zeiss confocal microscope. 
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Immunohistochemistry 
Fresh human subcutaneous adipose tissue was cut into 1 cm2 pieces and washed with PBS to 
remove excess blood. Next, the tissue was submerged in 4% ice-cold PFA for four hours, then 
washed with PBS for 30 minutes twice and left in PBS overnight at 4oC. The tissue was then 
sequentially submerged in increasing concentrations of ethanol (30, 50, 70, 90, 95, 100% and 
100%) for one hour each to dehydrate the tissue. The tissue was then submerged in histo-clear 
(National Diagnostic, Atlanta, GA, USA) for one hour and embedded into paraffin by placing 
the tissue in molten paraffin for two hours twice and the embedded tissue was placed in a mould 
and encased in paraffin. The paraffin embedded tissue was then left overnight at 4oC to set. 
The tissue was subsequently cut into 6 μm sections using a Microm HM355S automatic 
microtome (Thermo Fisher Scientific, Waltham, MA, USA) and mounted onto (3-
aminopropyl)triethoxysilane coated glass slides. When the slides were dry, the sections were 
dewaxed with histo-clear (5 minutes twice) and rehydrated by sequentially submerging the 
sections in decreasing concentrations of ethanol (100, 95, 80, 70, 50 and 30% for 1 minute 
each), followed by distilled water for 1 minute. The dewaxed sections were then stained using 
an Anti-rabbit or Anti-goat HRP-DAB Cell & Tissue Staining Kit purchased from R and D 
systems (Minneapolis, MN, USA) as per the manufacturer’s instructions. The sections were 
incubated with primary antibodies for P2Y1 (Santa Cruz Biotechnology Cat# sc-20123, 
RRID:AB_2158393)), P2Y2 (Santa Cruz Biotechnology Cat# sc-20124, RRID:AB_2156139)) 
or P2Y12 (Santa Cruz Biotechnology Cat# sc-27152, RRID:AB_2155964) (1:200 in PBS with 
1% BSA) or PBS with 1% BSA alone overnight at 4oC. All primary antibodies were purchased 
from Santa Cruz Biotechnology (Dallas, TX, USA). When the staining protocol was complete, 
the sections were dehydrated again by rapidly dipping the slides in increasing concentrations 
of ethanol, and then histo-clear for 10 minutes and finally mounted with DPX mountant. Once 
the mountant was dry, images of stained sections and no primary antibody controls were taken 
using an Olympus CKX41 inverted microscope (Olympus, Tokyo, Japan).  
 
RNA extraction and cDNA synthesis  
In vitro differentiated adipocytes were lysed with TRI-reagent and then treated with 100 μl 1-
bromo-3-chloropropane and centrifuged to partition the sample. The top aqueous phase was 
then carefully transferred into a fresh tube and the RNA was precipitated with isopropanol and 
washed with 75% ethanol. The RNA was then centrifuged at 12,000 x g for 10 minutes, the 
supernatant was removed and the RNA pellet was air dried. The RNA was then resuspended 
in molecular grade water and potential genomic DNA contamination was removed using a 
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DNA-freeTM DNA removal kit (Thermo Fisher Scientific, Waltham, MA, USA) as per the 
manufacturer’s instructions. The purity and quantity of RNA was assessed using a Nanodrop 
2000 (Thermo Scientific, Wilmington, DE, USA).  
 
500 ng of RNA for each sample was primed with 100 ng random hexamer primers (Bioline, 
Taunton, MA, USA) by heating the mixture to 70oC for 10 minutes. Each sample was then 
incubated with 250 μM dNTPs (Bioline, Taunton, MA, USA), 30 U RNasin ribonuclease 
inhibitor (Promega, Madison, WI, USA), 0.01M DTT, first strand buffer and 200 U Superscript 
III Reverse transcriptase (RT) (Thermo Fisher Scientific, Waltham, MA, USA) for 1 hour at 
42oC. A duplicate sample with no RT was run alongside as a control for genomic DNA 
contamination. The PCR reaction was terminated by heating the samples to 70oC for 10 
minutes. Complementary DNA (cDNA) samples were then stored at -20oC.   
 
Quantitative RT PCR 
The cDNA and their corresponding no RT controls were diluted to 2 ng/μL and mixed with 
TaqManTM fast universal PCR master mix (Thermo Fisher Scientific, Waltham, MA, USA). 
Commercially available TaqMan gene expression assay primers and probes for each gene of 
interest (GOI) were also added (P2Y1 Hs00704965_s1; P2Y2 Hs04176264_s1; P2Y4 
Hs00267404_s1; P2Y6 Hs00366312_m1; P2Y11 Hs01038858_m1; P2Y12 Hs01881698_s1; 
P2Y13 Hs03043902_s1; P2Y14 Hs01848195_s1; P2X1 Hs00175686_m1; P2X2 
Hs04176268_g1; P2X3 Hs01125554_m1; P2X4 Hs00602442_m1; P2X5 Hs01112471_m1; 
P2X6 Hs01003997_m1; P2X7 Hs00175721_m1; RPLP0 Hs99999902_m1). Each sample was 
then amplified in a MicroAmp fast optical 96-well reaction plate on an Applied Biosystems 
7500 Real-Time PCR System (Thermo Fisher Scientific, Waltham, MA, USA) for 40 cycles. 
Threshold cycle (CT) values were extracted from the 7500 software v2.0.6. Receptors with CT 
values of below 35 were deemed to be expressed. Ribosomal protein lateral stalk subunit P0 
(RPLP0) was used as an endogenous control to normalise for any variability in cDNA template 
input.  
 
RT PCR 
cDNA (or no RT control sample) (1 μg) was mixed with 25 μl of ReadyMix™ Taq PCR 
Reaction Mix, 0.2 μM forward primers, 0.2 μM reverse primers and water to achieve a total 
volume of 50 μl. The following PCR conditions were employed for each GOI: Initial 
denaturation at 94oC for 1 minute, then 35 cycles of 94oC for 30 seconds, variable annealing 
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conditions according to GOI and 72oC for 1 minute, followed by 5 minutes at 72oC for the final 
extension. The annealing conditions were 55oC for 30 seconds for all primer sequences, 
excluding adenylate cyclase type 2, 3, 8 and 9 that had an annealing temperature of 52oC (1 
minute) and adenylate cyclase type 7, which had an annealing temperature of 45oC (1 minute).  
Primer sets used: adenylate cyclase type 1: sense 5’ CAT GAC CTG CGA GGA CGA T 3’, 
anti-sense 5’ ACA GGA GAC TGC GAA TCT GAA 3’; type 2: sense 5’ GGG GCT GCG 
TTT CTC T 3’, anti-sense 5’  CAG GAA CAC GGA ACA GGA TA 3’; type 3: sense 5’ CAC 
GGG ACC CAG CAA T 3’, anti-sense 5’ GCT CTA AGG CCA CCA TAG GTA 3’; type 4: 
sense 5’ TCC AAG CTC CCA ATG TGT CC 3’, anti-sense 5’  CTT GTC CAG AGG TGG 
CAT TT 3’; type 5: sense 5’ TCT GGT CTA ACG ATG TCA CGC 3’, anti-sense 5’ TCT TTC 
CGC TTC TGG GTG C 3’; type 6: sense 5’ GGC ATT GAT GAT TCC AGC AAA GAC 3’, 
anti-sense 5’ TGC AGG GCC TTA GGG AAC AGA 3’; type 7: sense 5’ CCA GTC TGG 
ATG CAC AGG AG 3’, anti-sense 5’ AGC CTC CCA TCA AAG AAC CG 3’; type 8: sense 
5’ CGG GAT TTG GAA CGC CTC TA 3’, anti-sense 5’ CCG GTC TGA CAG GTA ACT 
GAT AA 3’; type 9: sense 5’ CAC CGC AAA ATA CTT AGA TGA CG 3’, anti-sense 5’ CCT 
TCT CCT GCA AGA TCT CAC AC 3’.  
 
Glycerol quantification assay 
In vitro differentiated adipocytes were washed once with PBS and then incubated with 100 
μl/well DMEM (without serum or antibiotics) for 2 hours at 37oC with 5% CO2. Immediately 
following this incubation period, 1 μl/well vehicle or antagonist was added directly to each 
well and the cells were incubated for a further 30 minutes at 37oC with 5% CO2. Next, a further 
50 μl/well DMEM containing vehicle or agonists was added to each well. For the time series 
assays, a sample was collected immediately after the agonist was added by gently pipetting to 
mix and then 100 μl/well supernatant was removed and placed in a fresh 96 well plate and kept 
on ice for the duration of the experiment. These initial samples were labelled ‘0 minutes’, and 
then samples were taken after 20, 40, 60, 120 and 180 minutes had lapsed. The cells were 
incubated at 37oC with 5% CO2 between sample intervals. Alternatively, for all non-time series 
glycerol experiments, samples were taken three hours after vehicle/agonist was added. After 
the final sample was collected, all the samples were then stored at -80oC or used immediately 
for the glycerol quantification assay. A glycerol assay kit was purchased from Sigma Aldrich 
(Dorset, UK) and performed as per the manufacturer’s instructions. A standard curve was run 
with each assay run. Due to variation in basal glycerol levels between donors, the data was 
normalised to the amount of glycerol produced under the control conditions after 3 hours.  
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 ATP quantification assay 
In vitro differentiated adipocytes were washed once with PBS and then incubated with 50 
μl/well DMEM (without serum or antibiotics) for 1 hour at 37oC with 5% CO2. Next, 1 μl 
vehicle or antagonist was added directly to each well and the cells were incubated for a further 
1 hour at 37oC with 5% CO2. The supernatant was then carefully removed, taking care not to 
disturb the cells, and the ATP was quantified using an ATP Bioluminescence Assay Kit HS II 
(Roche, Mannheim, Germany) performed as per the manufacturer’s instructions. A standard 
curve was run with each assay. An integration time of 1 second was used for the 
bioluminescence readings. ATP levels in cell-free culture medium in each experimental 
condition were quantified and subtracted from test samples. The total cell number and 
supernatant volume were standardised for all experiments.  
 
Cyclic AMP quantification assay 
In vitro differentiated adipocytes were washed once with PBS and then incubated with 100 
μl/well DMEM (no serum or antibiotics) for 2 hours at 37oC and then the 1 μl/well 
vehicle/antagonist was added to each well and the cells were incubated for a further 30 minutes 
at 37oC. DMEM alone or agonist (50 μl/well) was added to each well and the cells were 
incubated for a further 15 minutes at 37oC. The cells were then washed twice with ice-cold 
PBS and lysed on ice with 100 µl/well 1x cell lysis buffer containing 1 mM 
phenylmethylsulfonyl fluoride. The rest of the assay was performed as per the manufacturer’s 
instruction for the Cyclic AMP XP® Assay Kit (Cell Signalling Technology, Leiden, The 
Netherlands).  
 
Lentiviral shRNA knockdown 
Bacterial glycerol stocks of pLKO.1 puro vectors carrying Mission® non-target shRNA control 
sequences or shRNA sequences that targeted the P2Y2 gene (TRCN0000009481) were 
purchased from Sigma-Aldrich (Dorset, UK). Bacterial stocks of psPAX2 (viral packaging 
plasmid) and pMD2.G (viral envelope plasmid) were purchased from Addgene (Cambridge, 
MA, USA). HEK239/17 cells (ATCC Cat# CRL-11268, RRID:CVCL 1926) were transfected 
with 12 μg psPAX2, 3 μg pMD2.G and 9 μg non-target shRNA control plasmid DNA 
(scrambled control) or plasmid DNA containing shRNA targeting P2Y2 (P2Y2 shRNA), in the 
presence of LipofectamineTM 2000 (Thermo Fisher Scientific, Waltham, MA, USA). The 
HEK293/17 cells were grown in normal culture media (DMEM with 10% FBS and 1% 
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antibiotics) and this was exchanged for 20 ml of viral collection media (DMEM supplemented 
with 1% FBS and no antibiotics) immediately before adding the plasmid DNA and 
lipofectamine, which was diluted in 1.2 ml of OPTI-MEM media (Thermo Fisher Scientific, 
Waltham, MA, USA), drop-wise to the cells. The cells were then incubated for 6 hours with 
this mixture at 37oC in 5% CO2. The media was then replaced with fresh viral collection media 
and then cells were left to incubate at 37oC in 5% CO2 for 72 hours, with the media being 
collected (and stored at 4oC) and replaced with fresh viral collection media every 24 hours. 
After 72 hours had lapsed, the virus containing media was passed through a 0.45 um filter to 
remove cell debris and then the virus was concentrated using Lenti-X concentrator solution 
(Clontech, Fremont, CA, USA) as per the manufacturer’s instructions. The resulting 
concentrated virus was then aliquoted and stored at -80oC until required. A p24 ELISA was 
performed using a QuickTiterTM Lentivirus Titer Kit (Cell Biolabs Inc, San Diego, CA, USA) 
as per the manufacturer’s guidelines to calculate the multiplicity of infection (MOI) for both 
the scrambled control and P2Y2 shRNA lentiviral particles. These values were then used to 
ensure that equivalent amounts of control and target lentivirus were used for subsequent 
experiments.  
 
In vitro differentiated adipocytes were washed once with PBS and 200 μl/well of fresh culture 
media (DMEM containing 10% FBS and antibiotics) was added to each well. Then 8 μg/ml 
polybrene and scrambled control or P2Y2 shRNA lentiviral particles (MOI of 1000) was added 
to each well and the cells were incubated for 18 hours at 37oC in 5% CO2. The following day, 
the media was removed and replaced with fresh culture media and the cells were incubated for 
a further four days at 37oC in 5% CO2 before they were ready for experimental use. Following 
experimental use, the cells were lysed and successful P2Y2 knockdown was confirmed using 
quantitative RT PCR.  
 
BODIPY staining 
In vitro differentiated adipocytes transfected with scrambled control or P2Y2 shRNA lentiviral 
particles were stained with BODIPY 493/503 lipid dye (Thermo Fisher Scientific, Waltham, 
MA, USA) to quantitate any changes in total lipid content due to reduction of P2Y2 expression. 
To do this, the culture media was removed and replaced with 100 μl/well DMEM (no FBS or 
antibiotics) and a further 100 μl/well of DMEM containing 2 μM BODIPY 493/503 dye was 
added and immediately mixed thoroughly by gently pipetting. The cells were then incubated 
for 30 minutes at 37oC in the dark. The excess dye was then removed and the cells were washed 
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twice with PBS and then the fluorescence at 493/503 nm (excitation/emission) was measured 
using a Flexstation III microplate reader. Each experiment was normalised for background 
fluorescence, by measuring and subtracting the fluorescence values for cells in the absence of 
the dye.  
 
Lipid droplet quantification 
Images of human in vitro differentiated adipocytes that had been treated with both scrambled 
and P2Y2 shRNA lentiviral particles were taken using an Olympus CKX41 inverted 
microscope for 12 independent donors. These images were then anonymised to eliminate 
operator bias and analysed using the counter plugin on Image J (NIH, Bethesda, MD, USA). 
The number of lipid droplets in 15 individual cells from each image were quantified. Once all 
the counting was complete, the values were sorted according to whether they were calculated 
from an image of scrambled or P2Y2 knockdown adipocytes to perform statistical analyses.   
 
Adipokine array 
In vitro differentiated adipocytes were washed once with PBS and then incubated with 100 
μl/well DMEM (no serum or antibiotics) for 2 hours at 37oC in 5% CO2. Next, 1 μl/well of 
vehicle or antagonist was added to each well and the cells were incubated for a further 30 
minutes at 37oC in 5% CO2, then the first supernatant samples were taken for the 0 hour time 
point by gently pipetting up and down and then transferring 75 μl/well into a fresh 96 well 
plate. Additional samples were taken in this manner after 3 hours and 24 hours. All the samples 
were stored at -80oC until required.  
 
A Human Obesity Array Q3, which has the capacity to detect 40 human adipokine, was 
purchased from RayBiotech (Norcross, GA, USA). When supernatant samples had been 
collected from four independent donors, the samples were defrosted and allowed to warm to 
room temperature before conducting the protein array. The protein array was then performed 
as per the manufacturer’s instruction and sent back to the manufacturer for analysis. The 
median fluorescence values were used for adipokine quantification analysis and a heat map 
was generated by normalising the average adipokine concentrations to the vehicle control.    
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Statistical analysis 
Results were analysed, including statistical analyses, using Origin Pro 2017 software (Origin 
Lab, Northampton, MA, USA). All concentration response data were normalised to the 
maximal response. In cases of variability between donors, the concentration that produced the 
maximum response in the majority of donors was used. Data were normalised to their 
respective vehicle controls. Concentration response curves were fitted by Origin using the Hill 
Equation. N applies to number of donors throughout.  
 
Data were assessed for normality using a Shapiro-Wilk test and then normally distributed data 
were assessed using a paired/unpaired Student’s t-test or ANOVA with a post hoc Tukey test. 
Non-normally distributed data were assessed by paired sample Wilcoxon signed rank test, 
Mann-Whitney test or Kruskal-Wallis ANOVA with a post hoc Dunn’s test. Data are expressed 
as mean ± SEM of experiments performed in duplicate using cells from a minimum of three 
independent donors. 
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Figure 1 Extracellular ATP, ADP and UTP elicited intracellular Ca2+ responses in human 
adipocytes. (A) Representative image of human adipocytes in culture. Scale bar represents 
100µm.  (B)  Time-resolved intracellular Ca2+ responses for maximal concentrations of ATP, 
ADP and UTP (N=6).  Traces are normalized to peak response.  (C) Concentration response 
relationship for Ca2+ responses evoked by ATP (closed circles), ADP (open circles) and UTP 
(open triangles) (N=6).  (D) Chart to show significant differences in Ca2+ response maxima 
evoked by nucleotides at maximal concentrations (ATP, 30µM; ADP, 10µM; UTP, 100µM) 
(N=6; *P<0.05).  (E) Time resolved intracellular Ca2+ response evoked by ATP in the presence 
(closed circles) and absence (open circles) of extracellular Ca2+ (N=6).  (F)  ATP concentration-
response curve in the presence (closed circles) and absence (open circles) of extracellular Ca2+ 
(N=6).  (G) Effect of phospholipase C inhibition on intracellular Ca2+ responses evoked by 
ATP.  Ca2+ signal evoked by ATP in the presence (open circles) and absence (closed circles) 
of 10µM U73122 (N=6). (H) Concentration-response curve for ATP in the presence (open 
circles) and absence (closed circles) of 10µM U73122 (N=6). F ratio represents the emission 
ratio of Fura-2 throughout. N represents number of donors (biological repeats).  
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Figure 2 P2Y1, P2Y2 and P2Y12 receptor activation mediates ATP-evoked Ca2+ signaling 
and P2Y1 and P2Y12 receptor activation mediates ADP-evoked Ca2+ signaling in human 
adipocytes.  (A)  Effect of P2Y subtype selective antagonists on Ca2+ responses evoked by 
30µM ATP. Concentration-inhibition curve for MRS2500 (P2Y1; closed circles), AR-
C118925XX (P2Y2; open circles) and PSB0739 (P2Y12; triangles) (N=6).  Responses are 
normalized to the agonist response in the presence of vehicle control only. (B-D) Time resolved 
Ca2+ response evoked by ATP in the presence (open circles) and absence (closed circles) of 
1µM MRS2500 (B), 10µM AR-C118925XX (C) or 10µM PSB-0739 (D) (N=6). Traces are 
normalized to peak agonist response in the presence of vehicle control only.  (E) Chart to show 
effects of individual antagonists (MRS2500, 1µM; AR-C118925XX, 10 µM; PSB-0739, 
3µM), or in combination, on the magnitude of Ca2+ response evoked by 30µM ATP (N=6; 
*P<0.05 versus vehicle control).  (F) Effect of P2Y1 and P2Y12 receptor antagonists subtype 
selective inhibitors on Ca2+ responses evoked by 10µM ADP. Concentration-inhibition curve 
for MRS2500 (P2Y1; closed circles) and PSB-0739 (P2Y12; open circles) (N=6). (G and H) 
Time resolved Ca2+ response evoked by ADP in the presence (open circles) and absence 
(closed circles) of 1µM MRS2500 (G), 3µM PSB-0739 (H) or 10μM AR-C118925XX (N=6).  
(I) Chart to show effects of individual antagonists (MRS2500, 1µM; PSB-0739, 3µM), or in 
combination, on the magnitude of Ca2+ response evoked by 10µM ADP (N=6; *P<0.05 versus 
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vehicle control). (J) Effect of 100 ng/mL pertussis on Ca2+ responses evoked by ATP (J) or 
ADP (K).  Traces shown are for vehicle control (closed circles) or with pertussis toxin (open 
circles). F ratio represents the emission ratio of Fura-2 throughout. N represents number of 
donors (biological repeats). 
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Figure 3 Expression of purinergic receptors in human adipocytes and adipose tissue.  (A) 
Quantitative RT-PCR analysis of P2Y and P2X receptor subtypes expressed by adipocytes 
(N=6 donors). Expression is given relative to the housekeeper gene, RPLP0. (B) 
Immunocytochemical staining of purinergic receptor subtypes in human adipocytes. Rabbit 
polyclonal primary antibodies against P2X4, P2X7, P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y13 
receptors, and goat polyclonal primary antibodies against P2X5 and P2Y12 receptors are used. 
Green channel shows fluorescence arising from secondary anti-rabbit or anti-goat Alexa 488-
conjugated antibodies. (-goat neg or -rabbit neg) Non-specific binding negative controls for 
secondary antibodies.  Blue channel shows nuclei counterstained with DAPI. Scale bar is 
30µm. Images are representative of at least 10 fields of view for 3 donors. (C) anti-P2Y1, anti-
P2Y2 and anti-P2Y12 immunoreactivity in 6µm sections of human abdominal subcutaneous 
white adipose tissue. Immunoreactivity visualized using a HRP-conjugated secondary 
antibody. Non-specific secondary binding controlled for in the absence of anti-P2Y receptor 
antibody (no primary controls). Scale bar is 200µm. 
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Figure 4 Adipocyte cytoplasmic Ca2+ tone generated by constitutive ATP release and 
P2Y2 receptor activation.  (A) Luciferase bioluminescence measurement of extracellular ATP 
in culture medium conditioned by human adipocytes under control conditions and following 
extracellular ATP scavenging with apyrase (4U/mL) (N=3).  (B) Resting cytoplasmic Ca2+ in 
adipocytes in control conditions or following treatment with apyrase (4U/ml) for 30 minutes 
(N=4).  (C-E) Effect of P2Y receptor subtype antagonists on adipocyte resting cytoplasmic 
Ca2+. Cells treated with MRS2500 (C; 1µM; P2Y1), AR-C118925XX (D; 10 µM; P2Y2) or 
PSB-0739 (E; 1µM; P2Y12) for 30 minutes or vehicle (control) (N=6). Ca
2+ concentrations are 
calculated via the calibration of the ratiometric Ca2+ indicator Fura-2.  *P<0.05 versus control 
throughout; NS is non-significant; N represents number of donors (biological repeats). 
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Figure 5 P2Y2 receptor antagonism or knockdown enhances basal lipolysis in human 
adipocytes.  (A)  Basal lipolysis measured in adipocytes in culture by glycerol release. 
Adipocytes are in the presence of vehicle (closed circles) or with P2Y2 antagonist (AR-
C118925XX, 10 µM; open circles) (N=3). (B) Concentration dependent enhancement of basal 
lipolysis by AR-C118925XX. Data is shown is for glycerol release after 3 hours as a percentage 
of vehicle control (N=3).  (C) Change in intracellular cyclic AMP in response to P2Y2 
antagonism (AR-C118925XX, 10 µM; 45 mins) over vehicle control (N=4).  (D) Change in 
basal lipolysis following shRNA-mediated P2Y2 receptor knockdown in adipocytes versus 
scrambled counterparts (N=3).  Glycerol release measured for 3 hours.  (E) Change in 
intracellular cyclic AMP in P2Y2 receptor knockdown adipocytes versus scrambled 
counterparts (N=3). (F) Representative (N=12) brightfield images to illustrate the small lipid 
droplet phenotype observed in P2Y2 receptor knockdown adipocytes versus scrambled 
counterparts. Scale bar is 50µm.  (G and H) Quantitation of number of lipid droplets (G; N=12) 
and neutral lipid content (H; BODIPY fluorescence; N=6) in P2Y2 receptor knockdown 
adipocyte versus scrambled counterparts.  (I and J) Lack of effect of P2Y1 receptor (I; 
MRS2500, 1µM; open circles; N=3) or P2Y12 receptor (J; PSB-0739, 3µM; open circles; N=5) 
antagonism on basal lipolysis. *P<0.05 versus control throughout; NS is non-significant; N 
represents number of donors (biological repeats).   
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Figure 6 P2Y2 receptor antagonism synergises with phosphodiesterase inhibition, but is 
dependent on adenylate cyclase activity in enhancing basal lipolysis in human adipocytes 
(A) Effect of antagonising phosphodiesterase (PDE) isoforms on basal lipolysis with and 
without P2Y2 antagonism. P2Y2 (AR-C118925XX, 10 µM), IBMX (pan PDE inhibitor; 
10µM), vinpocetine (PDE1; 10µM), PF-05180999 (PDE2; 10µM), cilostamide (PDE3; 1µM), 
rolipram (PDE4; 10µM) and BRL50481 (PDE7; 1µM) (N=3). Glycerol release after 3 hours 
expressed as percentage vehicle control.  (B) RT-PCR detection of adenylate cyclase isoforms 
in human adipocytes. Expected product sizes AC type 1 (446 bp), type 2 (369 bp), type 3 (263 
bp), type 4 (753 bp), type 5 (202 bp), type 6 (380 bp), type 7 (746 bp), type 8 (543 bp) and type 
9 (497 bp). Brain denotes positive control for AC type 9 expression. RT’ denotes absence of 
reverse transcriptase (negative control for genomic DNA).  (C)  Effect of P2Y2 receptor 
antagonism (AR-C118925XX, 10 µM) on basal lipolysis is reversed following adenylate 
cyclase inhibition (SQ22536, 1µM) (N=6). Basal lipolysis is measured as glycerol release over 
3 hours in all experiments. Antagonists were added 30 minutes prior to the start of the assay. 
*P<0.05 versus control throughout; N represents number of donors (biological repeats).  
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Figure 7 Longer term suppression of basal lipolysis in human adipocytes following 
P2Y2 receptor antagonism is associated with an anti-lipolytic adipokine 
profile.  (A) Glycerol release (basal lipolysis) measured 3 hours and 24 hours after singular 
exposure to vehicle (black bars) or P2Y2 antagonist (AR-C118925XX, 10µM; grey bars) 
(N=4).  (B) Heat map representing average change in secreted adipokines 24 hours after 
adipocyte exposure to vehicle or 10µM AR-C118925XX (N=4), as determined by quantitative 
protein array. Fold changes are expressed relative to levels of secreted adipokines before 
exposure to vehicle or AR-C118925XX. Bar charts showing significant increases in 
adiponectin and adipsin (negative regulators of lipolysis), and decrease in ANGPTL4 and RBP 
(positive regulators of lipolysis to illustrate shift to anti-lipolytic adipokine profile 24 hours 
after adipocyte singular exposure to 10µM AR-C118925XX (N=4). *P<0.05 versus 
control. N represents number of donors (biological repeats). 
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Figure 8 Schematic diagram of the proposed mechanism by which P2Y2 receptor 
activation causes acute suppression of lipolysis in primary human in vitro differentiated 
adipocytes.  Under basal conditions (left hand panel), P2Y2 receptors are activated by ATP or 
UTP released by the adipocytes into the extracellular space, which then subsequently activates 
phospholipase C (PLC) mediated production of diacylglycerol (DAG) and inositol triphosphate 
(IP3). The IP3 then binds to receptors on the surface of the endoplasmic reticulum (ER) to 
initiate release of calcium ions (Ca2+) from the ER into the cytosol. This elevation of 
cytoplasmic calcium causes tonic inhibition of calcium-sensitive adenylate cyclase (AC) 
isoforms. However, in the absence of P2Y2-receptor mediated inhibition of AC due to blockade 
of P2Y2 receptor signalling (right hand panel), intracellular calcium concentrations are lower 
and therefore AC is not inhibited and consequently free to convert ATP to cyclic AMP (cAMP). 
The increase in intracellular cAMP activates protein kinase A (PKA), which is then able to 
phosphorylate cytoplasmic hormone sensitive lipase (HSL). This allows HSL to translocate the 
lipid droplet. Here, adipose triglyceride lipase (ATGL) catalyses the hydrolysis of triglycerides 
(TG) to diglycerides (DG) and a free fatty acid (FA) molecule, then HSL catalyses the 
conversion of DG to monoglycerides (MG) and FA, finally monoglyceride lipase (MGL) 
catalyses lipolytic breakdown of MG to glycerol and FA. The glycerol and three FA molecules 
can then be transported out of the cell and released into the bloodstream, where they can travel 
to the liver or other organs to be utilised as an energy source 
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Supplementary Table 1 The effect of P2 subtype selective antagonism on the nucleotide-evoked calcium responses in primary human in vitro 
differentiated adipocytes. All the values in the maximum inhibition and IC50 columns were determined using cells from 6 independent donors. 
Selective 
antagonist 
Receptor 
target 
Nucleotide 
[concentration, µM] 
 Antagonist range, 
µM 
Maximum inhibition (%)a 
[antagonist concentration, µM] 
IC50, nMa Reference 
PSB-12062 P2X4 ATP [100] 0.003 – 30 NS - (Hernandez-Olmos et 
al. 2012) 
A438079 P2X7 ATP [1000] 0.003 – 10 NS - (Nelson et al. 2006) 
MRS2500 P2Y1 ATP [30] 0.0001 – 1 32.3 ± 3.8 [1] 
33.6 ± 3.6 [1] 
415 ± 160 
>1000 
(Kim et al. 2003) 
ADP [10] 0.0001 – 1 45.1 ± 4.7 [1] 
45.4 ± 6.9 [1] 
77.1 ± 37.5 
>1000 
AR-
C118925XX 
P2Y2 ATP [30] 0.003 - 30 20.4 ± 3.6 [10] 
47 ± 1.7 [10] 
683 ± 116 
434 ± 133 
(Rafehi et al. 2017) 
UTP [30] 0.003 - 30 100% 318 ± 399 
100% 474 ± 527 
MRS2578 P2Y6 ADP [30] 0.003 – 10 NS - (Mamedova et al. 2004) 
NF340 P2Y11 ATP [30] 0.003 - 10 NS - (Meis et al. 2010) 
ADP [10] 0.003 – 10 NS - 
PSB-0739 P2Y12 ATP [30] 0.003 – 10 46.8 ± 4.5 [10] 
44.5 ± 5.2 [10] 
<10,000 
<10,000 
(Hoffmann et al. 2009) 
ADP [10] 0.003 – 10 38.4 ± 5.1 [10] 
55.4 ± 4.4 [10] 
64.0 ± 56.5 
162 ± 25.4 
MRS2211 P2Y13 ATP [30] 0.003 – 3 NS - (Kim et al. 2005) 
ADP [10] 0.003 – 3 NS - 
aIC50 values and max % inhibition values were calculated with the peak magnitude values (top) and area under the curve data (bottom) for each agonist/antagonist combination. NS indicates no 
significant inhibition at any concentration of antagonist tested.
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Supplementary Table 2 The adipokine profile secreted by primary human in vitro 
differentiated adipocytes following singular treatment with vehicle or P2Y2 receptor 
antagonist (AR-C118925XX). Adipokines are quantified by protein array and data are 
presented as mean ± s.e.m for four donors.  
 Vehicle control 
(pg/ml) 
10 µM AR-
C118925XX (pg/ml) 
% increase 
or decrease  
Significance  
(p value) 
Adiponectin 8542.1 ± 1404 16001.1 ± 1156 ↑ 87% 0.000009 
Adipsin 1360.5 ± 208 5024.4 ± 1468 ↑ 269% 0.0005 
AgRP <14 <14 - - 
ANGPTL4 432.4 ± 45 119.7 ± 30 ↓ 72% 0.0007 
BDNF <55 <55 - - 
Chemerin 602.1 ± 140 374.6 ± 70 - 0.4 
CRP <27 12.6 ± 4 - 0.04 
GH <27 45.1 ± 11 ↑ 100% 0.03 
IFNγ <14 <14 - - 
IGFBP-1 15.3 ± 5 346.8 ± 28 ↑ 2162% 0.0005 
IGFBP-2 756.4 ± 57 262.9 ± 20 ↓ 65% 0.0000001 
IGF-1 4921.0 ± 1077 41515.3 ± 2087 ↑ 744% 0.0000000009 
IL-10 1.8 ± 0.5 8.5 ± 2 ↑ 369% 0.004 
IL-12p40 220.2 ± 95 32.2 ± 9 - 0.3 
IL-12p70 <3 <3 - - 
IL-1β 3.0 ± 0.9 6.1 ± 1 ↑ 104% 0.0004 
IL-1ra 358.0 ± 64 188.6 ± 48 ↓ 47% 0.02 
IL-6 836.4 ± 150 1547.0 ± 145 ↑ 85% 0.002 
IL-8 102.4 ± 21 181.4 ± 23 ↑ 77% 0.003 
Insulin 1127.1 ± 381 3767.1 ± 1673 - 0.99 
Leptin 271.1 ± 54 151.4 ± 25 - 0.99 
Lipocalin-2 3.0 ± 0.6 4.9 ± 1.4 - 0.1 
MSPa 182.3 ± 55 121.1 ± 39 - 0.5 
OPG 2309.1 ± 351 1775.1 ± 264 ↓ 23% 0.0009 
PAI-I 6450.2 ± 1172 1738.6 ± 322 ↓ 73% 0.0006 
PDGF-BB <3 <3 - - 
Pepsinogen 1 <27 <27 - - 
Pepsinogen 2 <55 <55 - - 
Procalcitonin 393.7 ± 120 <137  ↓ 100% 0.006 
RANTES 282.4 ± 98 53.5 ± 15 - 0.1 
RBP4 6459.1 ± 751 2739.7 ± 90 ↓ 58% 0.0009 
Resistin 579.2 ± 203 70.3 ± 21 ↓ 89% 0.04 
SAA <137 1816.1 ± 186 ↑ 100% 0.0005 
TGFβ1 <137 278.4 ± 66 ↑ 100% 0.006 
TSP-1 >200,000 >200,000 - 0.1 
TNF RI <137 <137 - - 
TNF RII 70.7 ± 7 24.7 ± 4 ↓ 65% 0.0006 
TNFa 98.8 ± 16 48.1 ± 8 ↓ 76%  0.006 
VEGF 1593.2 ± 73 979.0 ± 39 ↓ 39% 0.0000002 
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